| 2026-08-10 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | 8-K | Form 8-K, Item 1.01 |
| 2026-07-31 | 8-K | Form 8-K, Item 5.07 |
| 2026-07-30 | Press release | Amneal Reports Second Quarter 2026 Financial Results |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-29 | Deck | Amneal Pharmaceuticals Q2 2026 Earnings Call |
| 2026-07-17 | Press release | Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations |
| 2026-07-09 | Press release | Amneal to Report Second Quarter 2026 Results on |
| 2026-07-08 | Press release | Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector |
| 2026-07-01 | Press release | Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program |
| 2026-06-05 | Press release | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of C |
| 2026-06-04 | Press release | Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution |
| 2026-06-01 | Press release | Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 |
| 2026-05-29 | Document | crexont |
| 2026-05-07 | Press release | Amneal Reports First Quarter 2026 Financial Results ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒ |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Transcript | Q1 FY26 earnings call transcript |
| 2026-04-22 | Press release | Press release · Apr 2026 |
| 2026-04-22 | Press release | Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter · 2026 |
| 2026-04-22 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-20 | Press release | Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including |
| 2026-04-14 | Press release | Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S |
| 2026-04-09 | Press release | Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% |
| 2026-04-07 | Press release | Amneal to Report First Quarter 2026 Results on May 1, 2026 |
| 2026-04-07 | Press release | Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month |
| 2026-03-25 | Proxy | Definitive proxy statement |
| 2026-03-24 | Press release | Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Magnesium Sulfate in Water for Injection, USP 4 g/100mL |
| 2026-03-05 | Press release | Amneal to Participate in Upcoming Investor Conference |
| 2026-02-27 | Press release | Amneal Reports Fourth Quarter and Full Year 2025 Financial Results ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth |
| 2026-02-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-27 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-26 | Deck | Amneal Pharmaceuticals Q4 2025 Earnings Call |
| 2026-02-03 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-28 | Press release | Amneal Pharmaceuticals Added to S&P SmallCap 600® Index |
| 2026-01-28 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-27 | Press release | Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 |
| 2026-01-13 | 8-K | Form 8-K, Item 2.02 results |